CRISPR/Cas9 在癌症治疗中的应用:临床转化、机制策略与治疗方向 CRISPR/Cas9 in cancer therapy: clinical translation, mechanistic strategies, and therapeutic directions. PubMed 2026/07/17 发表Front OncolQ2 · IF 3.4(JCR 2025) 靶点:CD19靶点:BCMA技术:CAR-T技术:基因编辑血液系统恶性肿瘤实体瘤
CAR-T 细胞治疗在肿瘤免疫治疗中的应用——生物学、临床成功与新兴挑战:综述 CAR-T cell therapy in cancer immunotherapy - Biology, clinical successes, and emerging challenges: A review. PubMed 2026/05/26 发表Biomol BiomedQ3 · IF 2.8(JCR 2025) 靶点:CD19靶点:BCMA/CD19 双靶技术:CAR-T技术:NK 细胞技术:基因编辑急性淋巴细胞白血病非霍奇金淋巴瘤实体瘤
CAR 疗法在肿瘤与自身免疫领域的演进:机制见解与治疗创新 The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations. PubMed 2026/05/16 发表Int ImmunopharmacolQ1 · IF 5.6(JCR 2025) 靶点:CD19靶点:BCMA技术:CAR-T技术:基因编辑多发性骨髓瘤实体瘤淋巴瘤
CAR-T 细胞治疗的进展:抗原选择、改造及实体瘤当前试验 Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors. PubMed 2025/01/06 发表Front ImmunolQ1 · IF 7(JCR 2025) 靶点:CD19靶点:BCMA技术:CAR-T技术:基因编辑技术:mRNA血液系统恶性肿瘤实体瘤
非病毒转染系统制备的多重编辑 CAR-T 细胞功能效力增强 Increased functional potency of multi-edited CAR-T cells manufactured by a non-viral transfection system. PubMed 2024/12/05 发表Mol Ther Methods Clin DevQ2 · IF 5(JCR 2025) 靶点:CD19技术:CAR-T技术:基因编辑血液系统恶性肿瘤实体瘤地区:欧洲
新一代 CAR-NK 免疫疗法的工程化改造 Engineering the next generation of CAR-NK immunotherapies. PubMed 2021/08/28 发表Int J HematolQ3 · IF 1.9(JCR 2025) 靶点:CD19技术:CAR-T技术:CAR-NK技术:NK 细胞血液系统恶性肿瘤实体瘤